Compare
Enlivex Ltd. vs Core Scientific, Inc./tx vs Sharplink, Inc. vs Hyperliquid Strategies Inc
| Latest fiscal year | Enlivex Ltd. ENLV | Core Scientific, Inc./tx CORZ | Sharplink, Inc. SBET | Hyperliquid Strategies Inc PURRRevenue covers only part of its income (partial revenue) |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2026-06-30 |
| Revenue | n/a | $319.02M | $28.05M | n/a |
| Revenue growth (YoY) | n/a | -37.5% | +666.1% | n/a |
| Gross margin | n/a | 11.9% | n/a | n/a |
| Operating margin | n/a | -77.0% | n/m | n/a |
| Net margin | n/a | -90.5% | n/m | n/a |
| Net income | $1.24B | -$288.62M | -$734.59M | $305.54M |
| EPS (Diluted) | $25.48 | -$0.88 | -$7.37 | $3.21 |
| Operating cash flow | -$10.42M | $278.25M | -$17.54M | -$19.15M |
| Free cash flow | -$10.48M | -$450.75M | -$17.55M | n/a |
| Cash & equivalents | $1.89M | $311.38M | n/a | $137.92M |
| Total assets | $2.33B | $2.35B | $2.43B | $2.06B |
| Total liabilities | $392.05M | $3.31B | $12.75M | $187.14M |
| Shareholders' equity | $1.93B | -$962.74M | $2.42B | $1.87B |
| Return on year-end equity | 63.9% | n/a | -30.4% | 16.3% |
| Shares outstanding | 237.38M | 314.23M | 196.70M | 200.55M |
Revenue, most recent five fiscal years
| Fiscal year | Enlivex Ltd. | Core Scientific, Inc./tx | Sharplink, Inc. | Hyperliquid Strategies Inc |
|---|---|---|---|---|
| Latest | n/a | $319.02M Ended 2025-12-31 | $28.05M Ended 2025-12-31 | n/a |
| 1 year earlier | n/a | $510.67M Ended 2024-12-31 | $3.66M Ended 2024-12-31 | n/a |
| 2 years earlier | n/a | $502.40M Ended 2023-12-31 | $4.95M Ended 2023-12-31 | n/a |
| 3 years earlier | n/a | $640.31M Ended 2022-12-31 | $3.49M Ended 2022-12-31 | n/a |
| 4 years earlier | n/a | $544.48M Ended 2021-12-31 | n/a | n/a |